A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2015

Primary Completion Date

October 23, 2015

Study Completion Date

October 23, 2015

Conditions

Idiopathic Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Avacincaptad Pegol

Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.

Trial Locations (1)

Phoenix